Cancer Institute A national cancer institute
designated cancer center

James D. Brooks

Publication Details

  • Endothelin-1 promotes cell survival in renal cell carcinoma through the ETA receptor CANCER LETTERS Pflug, B. R., Zheng, H., Udan, M. S., D'Antonio, J. M., Marshall, F. F., Brooks, J. D., Nelson, J. B. 2007; 246 (1-2): 139-148

    Abstract:

    Endothelin-1 (ET-1) is a potent vasoconstrictor that has been shown to significantly impact many benign and malignant tissues by signaling through its two cognate receptors: ET(A) and ET(B). As ET-1 has a role in both normal and diseased kidney, we initiated studies to investigate endothelin axis expression and function in renal cell carcinoma (RCC). In this study, relatively high levels of ET-1 were detected in all six human RCC cell lines investigated. RT-PCR and Southern analyses revealed that all six RCC cell lines expressed ET(A) receptor mRNA, while 3/6 cell lines also expressed ET(B) mRNA. High affinity ET-1 binding occurred in all but one RCC cell line and quantitative RT-PCR demonstrated ET(A) mRNA expression in all six cell lines. Methylation of the ET(B) promoter (EDNRB) in 4/6 RCC cell lines was observed, suggesting a mechanism for repressed ET(B) expression. Moreover, methylation occurred in 32/48 of renal tumors and in 27/55 of histologically normal adjacent tissue samples studied, while no methylation was evident in any normal tissue isolated from nephrectomy or at autopsy. Functionally, ET-1 significantly inhibited paclitaxel-induced apoptosis in RCC cells through binding ET(A) with the ET-1 signaling mediated via the PI3-kinase/Akt pathway. Collectively, these data support the therapeutic targeting of the ET(A) receptor as a novel treatment strategy for RCC.

    View details for DOI 10.1016/j.canlet.2006.02.007

    View details for Web of Science ID 000244154900017

    View details for PubMedID 16581180

Stanford Medicine Resources:

Footer Links: